Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.02 is 336% above its 5-year average of -0.01, near the high end of its 5-year range (-47.22–0.67).
As of the fiscal period ended Tuesday, June 30, 2026. 47.59% below its 12-month average of 0.04.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.02.
DEBT TO EQUITY RATIO
0.02
DEBT TO EQUITY RATIO AVG TTM
0.04
DEBT TO EQUITY RATIO AVG 3Y
-0.13
DEBT TO EQUITY RATIO AVG 5Y
-0.01
DEBT TO EQUITY RATIO AVG 10Y
0.07
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-47.59%
CURRENT VS 3Y AVG
+115.04%
CURRENT VS 5Y AVG
+335.78%
CURRENT VS 10Y AVG
-74.31%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 564 covered companies
CURRENT VS SECTOR MEDIAN
-85.47%
vs the sector median at left
CytomX Therapeutics, Inc.
Market Cap
$563.87M
Debt to Equity Ratio
0.02
TTM Avg
0.04
3Y Avg
-0.13
5Y Avg
-0.01
Market Cap
$560.00M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$559.21M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.05
Market Cap
$568.99M
Debt to Equity Ratio
N/A
TTM Avg
4.68
3Y Avg
4.68
5Y Avg
4.68
Market Cap
$556.76M
Debt to Equity Ratio
0.28
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$545.59M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$582.66M
Debt to Equity Ratio
0.27
TTM Avg
0.26
3Y Avg
0.14
5Y Avg
0.13
Market Cap
$537.09M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.23
5Y Avg
0.43
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | $563.87M | 0.02 | 0.04 | -0.13 | -0.01 |
| CorMedix Inc. (CRMD)vs › | $563.68M | 0.31 | 0.19 | 0.10 | 0.07 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $559.21M | 0.00 | 0.01 | 0.01 | 0.05 |
| Aquestive Therapeutics, Inc. (AQST)vs › | $568.99M | N/A | 4.68 | 4.68 | 4.68 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $556.76M | 0.28 | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $545.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| OrthoPediatrics Corp. (KIDS)vs › | $582.66M | 0.27 | 0.26 | 0.14 | 0.13 |
| Delcath Systems, Inc. (DCTH)vs › | $537.09M | 0.02 | 0.01 | 0.23 | 0.43 |
| Immix Biopharma, Inc. (IMMX)vs › | $534.50M | 0.00 | 0.04 | 0.02 | 0.02 |
Debt/Equity
0.02
Current Ratio
9.36
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.02 |
| 2026-03-31 | 0.01 |
| 2025-12-31 | 0.04 |
| 2025-09-30 | 0.05 |
| 2025-06-30 | 0.06 |
| 2025-03-31 | 0.33 |
| 2024-12-31 | -20.58 |
| 2024-09-30 | -0.45 |
| 2024-06-30 | -0.38 |
| 2024-03-31 | -0.41 |
| 2023-12-31 | -0.29 |
| 2023-09-30 | -0.29 |
| 2023-06-30 | -0.19 |
| 2023-03-31 | -0.20 |
| 2022-12-31 | -0.21 |
| 2022-09-30 | 0.67 |
| 2022-06-30 | 0.41 |
| 2022-03-31 | 0.31 |
| 2021-12-31 | -47.22 |
| 2021-09-30 | 0.20 |
| 2021-06-30 | 0.18 |
| 2021-03-31 | 0.17 |
| 2020-12-31 | -3.20 |
| 2020-09-30 | 0.53 |
| 2020-06-30 | 0.45 |
| 2020-03-31 | 0.39 |
| 2019-12-31 | 0.54 |
| 2019-09-30 | 0.35 |
| 2019-06-30 | 0.29 |
| 2019-03-31 | 0.24 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.04 |
| 2015-03-31 | -0.68 |
| 2014-12-31 | -0.04 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
